Trial Profile
Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin; Vinorelbine
- Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms JIPANG; JIPANG-TR
- 13 Sep 2022 Results of final analysis of OS in the JIPANG study is presented here presented at the 47th European Society for Medical Oncology Congress
- 24 Jun 2020 Results of exploratory study assessing relationship between tumor mutation profiles, including TMB and clinical outcome, of pemetrexed/cisplatin versus vinorelbine /cisplatin for completely resected stage II-IIIA non-squamous non-small-cell lung cancer in JIPAN study, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 14 May 2020 the primary end point was changed from overall survival to recurrence-free survival because, with developments in subsequent chemotherapy, death events were too few to evaluate survival at the completion of patient accrual